PSC
ASMB icon

Patient Square Capital’s Assembly Biosciences ASMB Stock Holding History

Patient Square Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-136,315
Closed -$3.78M – 24
2026
Q1 		$3.78M Buy
136,315
+9,315
+7% +$266K 0.67% 28
2025
Q4 		$4.32M Sell
127,000
-8,182
-6% -$264K 0.92% 24
2025
Q3 		$3.46M Buy
+135,182
New +$2.97M 0.93% 21

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Patient Square Capital's ASMB Position: Q2 2026 in Review

Patient Square Capital sold out of Assembly Biosciences (ASMB) in Q2 2026, closing a stake of 136,315 shares — an estimated $3.78M sold.

Patient Square Capital first reported a position in ASMB in Q3 2025 and held it in 3 quarters. The position peaked at $4.32M in Q4 2025. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Patient Square Capital reported no remaining Assembly Biosciences position as of Q2 2026 after selling out during the quarter.
  • Patient Square Capital sold 136,315 Assembly Biosciences shares in Q2 2026, an estimated $3.78M.
  • Patient Square Capital first reported a position in Assembly Biosciences in Q3 2025 and held it in 3 quarters.
  • Patient Square Capital's Assembly Biosciences position peaked at $4.32M in Q4 2025.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.